CRP and systemic inflammatory response syndrome: In addition, the impact of myosteatosis was maintained after adjustment for age, sex, diabetes status, and presence of SIRS on admission (model 1: HR, 4.585; 95% CI, 1.505–13.963; p = 0.007); for lymphocyte count, FIB-4 index, and CRP, inclusive of model 1 (model 2: HR, 3.667; 95% CI, 1.195–11.250; p = 0.023); and for body composition including sarcopenia and presence of visceral adiposity, along with the factors of model 2 (model 3: HR, 3.667; 95% CI, 1.195–11.250; p = 0.023) (Table 4).